Journal Article Summary
The article investigates the biodegradation process of a bimatoprost implant, which is designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This topic is significant because managing IOP is crucial for preventing vision loss in these patients, and the implant offers a potential alternative to daily eye drops. Understanding how the implant breaks down over time can help determine the best timing for re-administration and improve treatment strategies.
In the study, two phase 3 clinical trials were conducted with a total of 372 adult participants who received either a 10-μg or 15-μg bimatoprost implant. The implants were monitored over 20 months using gonioscopy to assess their size and location. Results showed that the biodegradation of the implants varied among patients, with significant degradation occurring within the first year. By the end of the study, 95% of the implants had degraded to either absent or less than 25% of their original size, primarily settling in the inferior part of the eye.
However, the study has limitations, including the potential influence of multiple implant administrations on the biodegradation of the first implant and the subjective nature of size estimates by investigators. Patients should be aware of these factors and discuss any concerns about the implant's effectiveness and safety with their healthcare provider. It is important to note that while the implant can provide long-lasting IOP control, the current recommendation is for a single administration to minimize risks of corneal adverse events. Ongoing studies are exploring the safety of re-administering the implant at longer intervals.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Weinreb Robert N., Bacharach Jason, Brubaker Jacob W., Medeiros Felipe A., Bejanian Marina, Bernstein Paula, Robinson Michael R.. Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies. Journal of Ocular Pharmacology and Therapeutics 2023. DOI: 10.1089/jop.2022.0137. PMID: 36378864. PMCID: PMC9885540.
Featured Pill Pals Product
Bimatoprost 0.03% Eyelid Solution --- 5 ML --- Generic for Latisse --- Sandoz
Bimatoprost 0.03% Eyelid Solution — 5 ML — Generic for Latisse — Sandoz is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
